News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Hemispherx Biopharma Updates Chronic Fatigue Syndrome (CFS) Treatment and Commercial Application Programs
November 2, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
PHILADELPHIA, Nov. 2, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), announced a two-prong CFS clinical mission for November and December 2009.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
MORE ON THIS TOPIC
China
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
July 27, 2026
·
10 min read
·
Heather McKenzie
Regulatory
Amgen deploys patients to defend troubled Tavneos in FDA hearing request
July 24, 2026
·
4 min read
·
Annalee Armstrong
Complete response letters
Update: FDA does not freeze CRL trove as ‘radical transparency’ push hits speedbump
July 23, 2026
·
3 min read
·
Tristan Manalac
China
US ‘eroding’ lead in rare diseases a matter of national security: Report
July 22, 2026
·
4 min read
·
Tristan Manalac
